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In the original article, the anti-PD1 clone ‘‘RMP1-14’’ was mistakenly written as ‘‘RPM1-14.’’ The reference for the study that gener-
ated the hybridoma clone is as follows: Yamazaki, T., Akiba, H., Koyanagi, A., Azuma, M., Yagita, H., and Okumura, K. (2005).
Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-g-induced nitric oxide production.
J. Immunol., 175, 1586–1592.
Additionally, in multiple points throughout the text, ‘‘Fcgr2b’’ should be ‘‘Fcgr2b,’’ ‘‘Fcgr1’’ should be ‘‘Fcgr1,’’ ‘‘Fcgr3’’ should be
‘‘Fcgr3,’’ and ‘‘Fcgr4’’ should be ‘‘Fcgr4.’’ Finally, in the first paragraph of the Discussion, ‘‘FcggR’’ should be ‘‘FcgR.’’
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